Icatibant Avansor

Icatibant, the active ingredient in Icatibant Avansor, is a bradykinin B2 receptor antagonist presented as a solution for injection for subcutaneous use. It treats hereditary angioedema attacks in patients with a confirmed diagnosis.

GNH USA supplies Icatibant Avansor as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Icatibant is a targeted therapy for hereditary angioedema, acting on the bradykinin pathway to relieve acute swelling.

Hereditary angioedema type I: rapid reduction of swelling during an attack. Hereditary angioedema type II: rapid reduction of swelling during an attack. Hereditary angioedema with normal C1‑INH (HAE‑nC1‑INH): symptom relief during acute episodes.

Icatibant is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Injection site pain or erythema. - Nausea or vomiting. - Headache. - Dizziness. - Fatigue.

Serious or Rare Side Effects: - Anaphylactic or severe hypersensitivity reactions. - Laryngeal edema leading to airway compromise. - Severe hypotension. - Thrombocytopenia. - Acute renal impairment.

Icatibant should be used with caution in specific clinical situations.

Pregnancy: safety not established; use only if benefit outweighs risk. Breastfeeding: unknown safety; consider discontinuation. Renal impairment: monitor closely, dose adjustment may be required. Concomitant ACE inhibitor therapy: increased risk of angioedema; assess necessity. Known hypersensitivity to icatibant or formulation components: contraindicated. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant may interact with other agents that influence bradykinin levels or vascular tone.

Major Interactions (Avoid): - ACE inhibitors: may potentiate bradykinin‑mediated angioedema. - Neprilysin inhibitors: increase bradykinin concentrations, raising risk of swelling.

Moderate Interactions (Monitor Closely): - Diuretics: may affect blood pressure when combined with icatibant. - Antihypertensive agents: monitor for additive hypotensive effects. - Other vasoactive drugs: observe for unexpected hemodynamic changes.